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Disseminated BCG disease is a rare life-threatening complication of BCG administration, characterised by
miliary pulmonary nodules. Presentation can mimic tuberculosis, both in symptoms and on radiological
imaging. Here we report a case of disseminated BCG disease following intravesical BCG treatment for
superﬁcial bladder cancer that responded to anti-tuberculous treatment and corticosteroids, and brieﬂy
review the literature on disseminated BCG disease.
 2011 Elsevier Ltd. All rights reserved.1. Educational aims
The educational aims of this manuscript are to
 To raise awareness of disseminated BCG disease as an adverse
effect of BCG administration.
 To describe the clinical presentation, including radiological
ﬁndings, of pulmonary involvement in disseminated BCG
disease.
 To describe the treatment of disseminated BCG disease.2. Introduction
The tuberculosis vaccine Bacillus CalmetteeGuérin (BCG)
contains live attenuated Mycobacterium bovis. In immuno-compe-
tent adults, disseminated BCG disease is a rare complication of
intravesical BCG treatment for superﬁcial bladder cancer that is
often characterised by miliary pulmonary nodules.1,2 Here we
report a case of disseminated BCG disease following intravesical
BCG treatment with features mimicking tuberculosis infection.3. Case report
A seventy-year-old man presented for assessment with a three-
week history of fever, lethargy and weight loss of 12 kg. He hadx: þ44 2920 708973.
les), rohan.mehta@wales.nhs.
rved.undergone transurethral resection of a superﬁcial bladder cancer
four months prior to presentation and subsequently received a six-
week course of intravesical BCG treatment (one dose per week).
Follow-up cystoscopy showed inﬂammatory changes only.
A further course of intravesical BCG was arranged but the patient
developed nausea, rigours and suprapubic pain within 24 h of
administration. These symptoms progressed into his presenting
illness.
Examination revealed normal pulse, blood pressure and respi-
ratory rate. Temperaturewas initially 36.3 C, but rose to39.2 C later
on that day. Oxygen saturations were 93% on room air. Examination
of the heart, chest and abdomen was normal. Initial blood tests
included a white blood cell count of 4.9  109/L and C-reactive
protein of 107mg/L. Chest X-ray showed no focal consolidationwith
minor bi-basal atelectasis. Urine dip-stick testing was positive for
red blood cells, protein, leucocytes and nitrites.
A provisional diagnosis of urinary tract infection was made and
treatment with oral ciproﬂoxacin was commenced. The patient
continued to have pyrexial episodes of 39 C over the next ﬁve days.
Three sets of blood cultures showed no bacterial growth, and the
urine specimen from admission showed sterile pyuria. In view of
the ongoing pyrexia, a CT scan of the thorax, abdomen and pelvis
was arranged. This revealed extensive nodularity throughout both
lungs (Fig. 1).
Three sputum samples showed no acid-fast bacilli or myco-
bacterial growth. A further set of blood and urine cultures showed
no growth. Bronchoscopy was macroscopically normal, but trans-
bronchial biopsy showed scattered epithelioid granulomas, with no
evidence of caseation or acid-fast bacilli.
A clinical diagnosis of disseminated BCG disease secondary to
intravesical BCG therapy was made. Treatment with rifampicin,
Fig. 1. Thoracic CT showing extensive pulmonary nodularity due to disseminated BCG
disease. The differential diagnosis of such an appearance would include miliary
tuberculosis.
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days of treatment the pyrexial episodes had not resolved. The addi-
tion of prednisolone to his treatment regime resulted in resolution of
the persistent pyrexia, and the patient was discharged home.
At follow-up after one month, reduction of the prednisolone
dose resulted in recurrence of rigours and weight loss. These
symptoms resolved with increasing the prednisolone dose, fol-
lowed by gradual tapering of steroid treatment.
4. Discussion
Disseminated BCG disease is a rare but life-threatening
complication of BCG administration. The spectrum of symptoms
may be similar to that of tuberculosis infection, including persistent
fever, night sweats and weight loss. The pathogenesis is thought to
involve a combination of mycobacteraemia and local inﬂammatory
hypersensitivity at various sites including the lungs. This is sup-
ported by the identiﬁcation of M. bovis in some reported cases3,4
and response to treatment with a combination of anti-
mycobacterial agents and corticosteroids.
There is currently no consensus on the optimum duration of
antimycobacterial or corticosteroid therapy in disseminated BCG
disease complicating intravesical BCG treatment. Triple-therapy
with rifampicin, isoniazid and ethambutol is the ﬁrst-line combi-
nation due to the inherent resistance ofM. bovis to pyrizinamide. In
our patient treatment was continued for nine months, thoughsuccessful treatment has been described after courses as short as
three months.5 Relapse in symptoms with reduction of corticoste-
roid dose has been reported previously,6 suggesting that a pro-
longed tapering course may be required.
Whilst disseminated BCG disease is rare following intravesical
BCG treatment in immuno-competent patients, the incidence
amongst childrenwith HIV infection following BCG vaccination has
been estimated to be as high as 992per 100,000.7 Symptoms include
fever and weight loss, and a systematic review reported a mortality
rate of 81%.7 The World Health Organization (WHO) currently
recommends thatHIV infection in infants is a full contraindication to
BCG vaccination.WHO also states that where feasible, infants at risk
of HIV infection should be tested for HIV prior to vaccination instead
of the previously recommended universal vaccination in countries
with a high burden of tuberculosis.8
In summary, disseminated BCG disease is a recognised compli-
cation of intravesical BCG therapy with symptoms and radiological
ﬁndings that maymimic tuberculosis infection. Treatment includes
corticosteroids in combination with antimycobacterial therapy.5. Patient consent
Written patient consent obtained.
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